Nightstar plans $86 million US offering

Nightstar Therapeutics Ltd plans to raise up to $86 million in an initial public offering (IPO) of its shares on Nasdaq to advance its portfolio of gene therapies to treat rare inherited retinal diseases. A registration document was filed with the US Securities and Exchange Commission on 31 August.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom